Phase I trial of EyeGate's non-invasive ocular drug delivery system launched

Article

A Phase I study testing safety and tolerability of a new non-invasive drug delivery system, the EyeGate II Ocular Drug Delivery System (EyeGate Pharma), has been launched.

A Phase I study testing safety and tolerability of a new non-invasive drug delivery system, the EyeGate II Ocular Drug Delivery System (EyeGate Pharma), has been launched. The new system is designed to treat serious ocular disease of both the front and the back of the eye, and uses a range of iontophoretic dose levels with a citrate buffer.

EyeGate Pharma has enrolled 95 healthy adult volunteers in the single centre, randomized, single masked, comparative group study, which is designed to establish the maximum tolerated current that can be employed during iontophoretic treatment with the EyeGate II Delivery System. An earlier study, assessing safety, tolerability and efficacy, enrolled 89 patients with severe ocular inflammation and demonstrated good patient tolerance, a decrease in inflammatory markers and an increase in visual acuity.

Two separate Phase II trials, for severe uveitis and dry eye, are planned for later this year.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.